The effect of radiation therapy combined with immunotherapy based on bio optical imaging on serum tumour markers and immune function in lung cancer patients: metabolic abnormality test.

Lung cancer is one of the malignant tumours with the highest incidence rate and mortality in the world, among which non small cell lung cancer (NSCLC) accounts for a relatively high proportion. Patients with locally advanced non-small cell lung cancer who cannot be surgically resected usually receive radiotherapy, but the effectiveness of a single treatment is limited. The results indicate that radiotherapy combined with immunotherapy has significant clinical efficacy in patients with locally advanced non-small cell lung cancer who cannot undergo surgical resection. Metabolic abnormality testing has important value in monitoring treatment efficacy and patient metabolic status, and can provide reference for optimising clinical treatment plans. Future research should further explore the application value of metabolic abnormality testing in the treatment of lung cancer, and combine it with other detection methods to provide more comprehensive and reliable treatment basis for clinical practice.